# Trade Mark Journal No.2025/044 31 October 2025

## WO0000001881539 (1,5,42)

Office of origin: United States of America

Date of International Registration:9 September 2025
Date of designation in the UK: 9 September 2025

International priority date claimed: 10 March 2025 (United States of America) (99075290)

Class 1
  Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use.
Class 5
  Pharmaceutical products for the treatment of cancer; antibodies for medical purposes.
Class 42
  Pharmaceutical products development; pharmaceutical research and development; research and development of medicines; research and development in the pharmaceutical and biotechnology fields; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research in the field of immunotherapy and immuno-oncology; research and development in the field of immunotherapy and immuno-oncology.

NextPoint Therapeutics, Inc.

Representative: Chang B. Hong Modality Law PLLC, 265 Franklin Street, Ste 1702, Boston MA 02110, UNITED STATES OF AMERICA